| Field | Specification |
|---|---|
| Target | |
| Alternative names | Receptor tyrosine-protein kinase erbB-2;2.7.10.1;Metastatic lymph node gene 19 protein;MLN 19;Proto-oncogene Neu;Proto-oncogene c-ErbB-2;Tyrosine kinase-type cell surface receptor HER2;p185erbB2;CD340;ERBB2;HER2, MLN19, NEU, NGL; |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | A synthetic peptide corresponding to a sequence at the N-terminus of human ErbB 2, identical to the related mouse and rat sequences. |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody targets receptor tyrosine-protein kinase erbB-2 (gene ERBB2) in human samples and is validated for IHC and Western blot. The predicted molecular weight is 137.9 kDa, and the supplier reports an observed band at about 185 kDa.
HER2 (ERBB2) is a receptor tyrosine kinase of the EGFR family that has no known ligand of its own but is the preferred partner for other ErbB receptors. Heterodimers containing HER2 signal strongly through MAPK and PI3K-AKT pathways. HER2 amplification drives a subset of breast and gastric cancers, making it one of the most studied oncology targets.
| Target | Receptor tyrosine-protein kinase erbB-2 (gene ERBB2; UniProt P04626, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4 |
| Calculated MW | 137.9 kDa |
| Observed MW | 185 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| IHC (paraffin sections) | 2–5 µg/mL (Human) |
|---|---|
| Western blot | 0.1–0.5 µg/mL (Human) |
Samples with a confirmed band (WB): human HeLa cells, human MCF-7 cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (IHC): human breast cancer tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Immunogen
Synthetic peptide from the N-terminal region of human erbB 2. The peptide sequence is conserved in mouse and rat.
Reactivity Notes
The supplier lists reactivity with human. UniProt places receptor tyrosine-protein kinase erbB-2 in the cell membrane and cell projection. Tissue expression noted by UniProt (human): Expressed in a variety of tumor tissues including primary breast tumors and tumors from small bowel, esophagus, kidney and mouth. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
Huile Gao et al. (2013) Incorporation of lapatinib into core–shell nanoparticles improves both the solubility and anti-glioma effects of the drug. International Journal of Pharmaceutics. 10.1016/j.ijpharm.2013.12.016
Tao Liu et al. (2011) In vitro study on human cytomegalovirus affecting early pregnancy villous EVT's invasion function. Virology Journal. 10.1186/1743-422X-8-114
Zhang Li et al. (2014) Lapatinib-incorporated lipoprotein-like nanoparticles: preparation and a proposed breast cancer-targeting mechanism. ACTA Pharmacologica Sinica. 10.1038/aps.2014.26
Weiwei Shang et al. (2013) MiR199b Suppresses Expression of Hypoxia-Inducible Factor 1α (HIF-1α) in Prostate Cancer Cells. International Journal of Molecular Sciences. 10.3390/ijms14048422
Han Yuanxing et al. (2025) KDM3A Modulates Trastuzumab Resistance in HER2− Positive Breast Cancer Cells via the PI3K/AKT/ERK Pathway. Biochemical Genetics. 10.1007/s10528-025-11170-8
